Kileza

Fulvestrant, the active ingredient in Kileza, is a selective estrogen receptor degrader (SERD) presented as an injectable formulation for intramuscular use. It is employed in hormone therapy to treat estrogen receptor‑positive metastatic breast cancer in adult patients.

GNH USA supplies Kileza as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kileza (fulvestrant) is used in the management of hormone‑driven breast cancer pathways.

- Estrogen receptor‑positive metastatic breast cancer: provides tumor growth inhibition after progression on prior endocrine therapy. - Hormone receptor‑positive advanced breast cancer: offers an alternative SERD option for patients with disease progression. - Postmenopausal women with ER‑positive disease: delivers targeted estrogen receptor degradation to control tumor spread.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the intramuscular injection site. - Hot flashes: transient episodes of warmth and sweating. - Nausea: occasional upset stomach or vomiting. - Fatigue: feeling of tiredness or reduced energy. - Arthralgia: joint pain or stiffness. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Hepatic toxicity: elevated liver enzymes or hepatitis. - Pulmonary embolism: sudden shortness of breath, chest pain, or coughing up blood. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention. - Tumor progression: rapid disease worsening despite therapy. - Hyperglycemia: significant rise in blood glucose levels.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Liver function monitoring: check ALT/AST levels regularly. - Thromboembolic risk assessment: evaluate history of clotting disorders. - Hypersensitivity evaluation: screen for prior allergic reactions to fulvestrant or excipients. - Osteoporosis caution: use with care in patients with severe bone loss. - Pregnancy and lactation: avoid use; safety unknown in pregnant or breastfeeding women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fulvestrant may interact with other medicines that affect its metabolism or therapeutic effect.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce fulvestrant exposure. - Concurrent estrogen therapy: can antagonize fulvestrant’s anti‑estrogen activity. - Co‑administration with other SERDs: may lead to overlapping toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase fulvestrant plasma levels. - Anticoagulants (e.g., warfarin): may alter INR and bleeding risk. - Herbal supplements such as St. John’s wort: could affect drug metabolism and efficacy.